Work

Impact of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms on antiepileptic drug safety and efficacy

Year: 2025

Type: article

Abstract: A review of literature data is presented on polymorphic variants of genes responsible for antiepileptic drugs (AEDs) pharmacokinetics: highly polymorphic cytochrome P450 isoenzyme genes CYP2C9 and CYP2C19 as well as the gene ABCB1 encoding transporter protein P-glycoprotein. Genetic variants in CYP2C9 and CYP2C19 reduce the rate of metabolism, leading to AED ineffectiveness and adverse effects. ABCB1 gene polymorphisms affect the expression of P-glycoprotein in the intestine and the blood-brain barrier, preventing drug penetration into the brain and leading to drug resistance. AEDs pharmacogenetic studies are of high medical priority, as they contribute to creating scientific foundation for personalized epilepsy treatment, development of drug dosing recommendations, increasing efficacy and safety of commonly administered AEDs. Further studies in different patient groups are needed to improve individualized epilepsy treatment in clinical practice.

Source: Epilepsy and Paroxysmal Conditions

DOI: 10.17749/2077-8333/epi.par.con.2025.240

Authors: N. A. Galankin, Z. G. Tadtaeva, I. S. Sardaryan, A. N. Galustyan, O. A. Gromova

Institutions: Saint Petersburg State Pediatric Medical University, Russian Academy of Sciences, Federal Research Center “Computer Science and Control” of the Russian Academy of Sciences

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $142